Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies

Oncologist

Volumn 12, Issue 12, 2007, Pages 1404-1415

  Costa, Luciano J ^a,c   Drabkin, Harry A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Medical University of South Carolina ^*  (United States)

Author keywords

Carcinoma; Interferons; mTOR protein; Protein tyrosine kinases; Renal cell; VEGF

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; IXABEPILONE; LAPATINIB; LIVER ENZYME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PAZOPANIB; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ANGIOGENESIS; BLEEDING; BLEEDING TENDENCY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL HYPOXIA; CELL SURVIVAL; CHILL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DIARRHEA; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEVER; GENE; GENE LOSS; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG EDEMA; METASTASIS; MOOD CHANGE; NEPHRECTOMY; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UPREGULATION; VHL GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38049088347     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-12-1404     Document Type: Review

References (99)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: A review. Cancer Invest 2005;23:240-255.
3. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005;338:627-638.
4. Soccio RE, Adams RM, Maxwell KN et al. Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. J Biol Chem 2005;280:19410-19418.
5. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
6. Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-1575.
7. Ohh M, Yauch RL, Lonergan KM et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
8. Esteban-Barragan MA, Avila P, Alvarez-Tejado M et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 2002;62:2929-2936.
9. Okuda H, Saitoh K, Hirai S et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001;276:43611-43617.
10. Esteban MA, Harten SK, Tran MG et al. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006;17:1801-1806.
11. Roe JS, Kim H, Lee SM et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006;22:395-405.
12. Appelhoff RJ, Tian YM, Raval RR et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:38458-38465.
13. Mansfield KD, Guzy RD, Pan Y et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005;1:393-399.
14. 2 sensing. J Biol Chem 2000;275:25130-25138.
15. Schroedl C, McClintock DS, Budinger GR et al. Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002;283:L922-L931.
16. Vanharanta S, Buchta M, McWhinney SR et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004;74:153-159.
17. Tomlinson IP, Alam NA, Rowan AJ et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410.
18. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
19. Kobayashi T, Hirayama Y, Kobayashi E et al. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995;9:70-74.
20. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-468.
21. Kondo K, Kim WY, Lechpammer M et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
22. Gemmill RM, Bemis LT, Lee JP et al. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 2002;21:3507-3516.
23. Gemmill RM, West JD, Boldog F et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci U S A 1998;95:9572-9577.
24. Poland KS, Azim M, Folsom M et al. A constitutional balanced t(3;8)(p14; q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. Genes Chromosomes Cancer 2007;46:805-812.
25. Brauweiler A, Lorick KL, Lee JP et al. RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene. Oncogene 2007;26:2263-2271.
26. Todd BL, Stewart EV, Burg JS et al. Sterol regulatory element binding protein is a principal regulator of anaerobic gene expression in fission yeast. Mol Cell Biol 2006;26:2817-2831.
27. Hughes AL, Todd BL, Espenshade PJ. SREBP pathway responds to sterols and functions as an oxygen sensor in fission yeast. Cell 2005;120:831-842.
28. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 2004;171:1071-1076.
29. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
30. Waters JS, Moss C, Pyle L et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91:1763-1768.
31. Nanus DM, Garino A, Milowsky MI et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551.
32. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982;20:177-181.
33. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
34. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
35. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141.
36. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132.
37. Quesada JR. Role of interferons in the therapy of metastatic renal cell carcinoma. Urology 1989;34(4 suppl):80-83; discussion 87-96.
38. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-17.
39. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
40. Rini BI, Halabi S, Barrier R et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006;12:778-785.
41. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-1043.
42. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
43. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
44. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
45. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
46. Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-7896.
47. Bukowski RM, Kabbinavar F, Figlin RA et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 2006;24:4523.
48. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25:3.
49. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002;298:1912-1934.
50. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-6392S.
51. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
52. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007;12:426-437.
53. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
54. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463.
55. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
56. Szczylik C, Demkow T, Staehler M et al. Randomized phase II trial of firstline treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 2007;25:5025.
57. Ryan C, Bukowski R, Figlin R et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts). J Clin Oncol 2007;25:5096.
58. Amato RJ, Harris P, Dalton M et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007;25:5026.
59. Ryan CW, Goldman BH, Lara PN et al. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol 2006;24:4525.
60. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
61. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16 -24.
62. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
63. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
64. Sablin MP, Bouaita L, Balleyguier C et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007;25:5038.
65. Hutson T, Davis I, Machiels J et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2004;25:5031.
66. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-5483.
67. Rini BI, Wilding GT, Hudes G et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 2007;25:5032.
68. Tamaskar I, Unnithan J, Garcia J et al. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. J Clin Oncol 2007;25:5048.
69. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.
70. Lee S, Chen TT, Barber CL et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.
71. Graff JR, Zimmer SG. Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003;20:265-273.
72. Kenerson HL, Aicher LD, True LD et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650.
73. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001;91:219-224.
74. Sabers CJ, Martin MM, Brunn GJ et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-822.
75. Garber K. Rapamycin's resurrection: A new way to target the cancer cell cycle. J Natl Cancer Inst 2001;93:1517-1519.
76. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6686.
77. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
78. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-2347.
79. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
80. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
81. Jac J, Giessinger S, Khan M et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007;25:5107.
82. Klapper LN, Waterman H, Sela M et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-3388.
83. Olayioye MA, Neve RM, Lane HA et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
84. Gomella LG, Sargent ER, Wade TP et al. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res 1989;49:6972-6975.
85. Humes HD, Beals TF, Cieslinski DA et al. Effects of transforming growth factor-beta, transforming growth factor-alpha, and other growth factors on renal proximal tubule cells. Lab Invest 1991;64:538-545.
86. Uhlman DL, Nguyen P, Manivel JC et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and prognosis. Clin Cancer Res 1995;1:913-920.
87. de Paulsen N, Brychzy A, Fournier MC et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001;98:1387-1392.
88. Knebelmann B, Ananth S, Cohen HT et al. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-231.
89. Dawson NA, Guo C, Zak R et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma Clin Cancer Res 2004;10:7812-7819.
90. Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006;24:4502.
91. Oya M, Ohtsubo M, Takayanagi A et al. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001;20:3888-3896.
92. Steiner T, Junker U, Henzgen B et al. Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur Urol 2001;39:478-483.
93. An J, Sun Y, Fisher M et al. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 2004;3:727-736.
94. Kondagunta GV, Drucker B, Schwartz L et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004;22:3720-3725.
95. Davis NB, Taber DA, Ansari RH et al. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004;22:115-119.
96. Gui CY, Ngo L, Xu WS et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-1246.
97. Yin D, Ong JM, Hu J et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007;13:1045-1052.
98. Juan LJ, Shia WJ, Chen MH et al. Histone deacetylases specifically downregulate p53-dependent gene activation. J Biol Chem 2000;275:20436-20443.
99. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.